Gut Microbiota Market Segmentation:
Application Segment Analysis
Therapeutics segment is poised to hold more than 60% gut microbiota market share by 2035, as increasing expenditure on biomedical, biopharmaceutical as well as biotechnology industries worldwide as well as increasing sales of biopharmaceuticals post-COVID -19. For instance, out of the total drug sales in 2021, biopharmaceuticals generated around 40% of global drug sales. Furthermore, the rising number of collaborations for R&D between market key players to better understand human gut health and develop apparent drug delivery systems to enhance the balance of gut microbiota besides the growing technological advancement in the therapeutics segment is further anticipated to boost the segment growth.
Disease Segment Analysis
Infectious segment is expected to capture over 45% gut microbiota market share by 2035, backed by the increasing prevalence of unspecified gastroenteritis as well as the growing number of suffering from patient diarrheal illnesses besides rising incident cases of acute gastrointestinal (GI) infections caused by Campylobacter, nontyphoidal Salmonella, Shigella, Escherichia coli (E. coli), or norovirus. For instance, a report stated that between the years 2010-2019, in the United States, the cases of unspecified gastroenteritis/diarrhea diagnoses accounted for over 98%. Moreover, nearly 2,241 cases of Campylobacter infections were diagnosed in the same period followed by Salmonella infections, Shigella, Escherichia coli (E. coli), or norovirus.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By Application |
|
|
By Disease |
|
